Condition: Primary IgA Nephropathy · Sponsor: Hoffmann-La Roche
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
This description comes directly from the study's public registry record.
Reference Study ID Number: WA43966 https://forpatients.roche.com/ · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Alabama Kidney Research - ERN - PPDS | Alabaster, Alabama, United States | Recruiting |
| UAB Nephrology Research Clinic | Birmingham, Alabama, United States | Recruiting |
| Sunrise Medical Management LLC | Surprise, Arizona, United States | Withdrawn |
| Tucson Neuroscience Research - M3 WR | Tucson, Arizona, United States | Withdrawn |
| Kidney Disease Medical Group Inc-1505 Wilson Ter | Glendale, California, United States | Recruiting |
| Southern California Medical Research Center | La Palma, California, United States | Withdrawn |
| Academic Medical Research Institute - Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica | Los Angeles, California, United States | Recruiting |
| Los Angeles County Nephrology | Montebello, California, United States | Recruiting |
| North America Research Institute-San Dimas | San Dimas, California, United States | Recruiting |
| Kaiser Permanente Skyport Medical Offices | San Jose, California, United States | Recruiting |
| BioResearch Partner ? Jackson West | Doral, Florida, United States | Recruiting |
+ 192 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05797610